XXXiaohu Xie

Xiaohu Xie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaohu Xie has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Wenhua Zhou

    Department of Psychiatry Affiliated Kangning Hospital of Ningbo University Ningbo Zhejiang China

    12 shared publications
  • Qingxiao Hong

    Zhejiang Key Laboratory of Drug Addiction and Brain Health, Ningbo, Zhejiang, 315201, People’s Republic of China

    7 shared publications
  • Huifen Liu

    Department of Psychiatry Affiliated Kangning Hospital of Ningbo University, Ningbo University Ningbo Zhejiang China

    6 shared publications
  • Weisheng Chen

    Department of Psychiatry Affiliated Kangning Hospital of Ningbo University, Ningbo University Ningbo Zhejiang China

    6 shared publications
  • Dingding Zhuang

    Key Laboratory of Addiction Research of Zhejiang Province, Ningbo Kangning Hospital, Ningbo, Zhejiang, China

    5 shared publications
  • Longhui Li

    Department of Psychiatry Affiliated Kangning Hospital of Ningbo University, Ningbo University Ningbo Zhejiang China

    5 shared publications

Latest Publications

  • Open Access

    Benzodiazepine Use Among Patients Receiving Methadone Maintenance Treatment: A Descriptive Study

    by Yue Liu, Qingxiao Hong, Wenwen Shen, Longhui Li, Zimeng Li, Wenhua Zhou, Xiaohu Xie

    Purpose: This study aimed to investigate the patterns and characteristics of benzodiazepine (BZD) use among patients receiving methadone maintenance treatment (MMT). Methods: A total of 80 participants (40 with and 40 without BZD use) were recruited from the MMT clinic of the Affiliated Kangning Hospital of Ningbo University between April 2024 and March 2025. All participants were assessed using the BZD Use Questionnaire (BUQ), the Chinese version of Barratt impulsiveness scale (BIS-C), the Self-rating Anxiety Scale (SAS), the Self-rating Depression Scale (SDS), and the Quality of Life Scale for Drug Addicts (QOL-DA). Results: Among 80 initially selected participants, 71 (BZD group: n=39; non-BZD group: n=32) were included in the final analysis after exclusions for invalid data. In univariate comparisons, the BZD group had a significantly higher prevalence of comorbid mental, sleep, and chronic disorders, higher scores on impulsivity (total, motor, and non-planning), anxiety, and depression scales, and lower scores on the total score as well as the psychological and symptoms/side effects domains of the QOL-DA (all P < 0.05). However, after adjusting for potential confounders, multivariate regression analyses indicated that BZD use was independently associated with higher anxiety levels (β = 0.279, P < 0.05) and greater total impulsivity (β = 0.439, P < 0.001). Regarding impulsivity subscales, BZD use was independently associated with non-planning (β = 0.265, P < 0.05) and motor impulsivity (β = 0.345, P < 0.05), but not with attentional impulsivity. No significant independent associations were found between BZD use and depression or any domain of quality of life (all P > 0.05). Conclusion: BZD use was independently associated with higher levels of impulsivity and anxiety after controlling for key comorbidities, but not with depression or QOL. The causal direction between BZD use and increased impulsivity/anxiety in MMT patients remains unclear, potentially reflecting either pharmacological effects or pre-existing higher levels of impulsivity or anxiety.


  • Open Access

    Epigenetic Landscapes of Methamphetamine Addiction: Unravelling the Diagnostic Potential of Gene Methylation

    by Qingxiao Hong, Shanshan Chen, Zhongze Lou, Weisheng Chen, Han Du, Longhui Li, Xiaohu Xie, Wenjin Xu, Wenhua Zhou, Huifen Liu

    Methamphetamine addiction is a chronic brain disorder involving significant neuroadaptive changes, with recent research emphasizing the role of epigenetic mechanisms, particularly DNA methylation. This study aims to evaluate the diagnostic potential of gene methylation by identifying and validating differentially methylated genes in methamphetamine‐dependent individuals versus healthy controls. A genome‐wide differentially methylated analysis was conducted using methylation microarray technology. Subsequently, pyrosequencing was employed for validation with an expanded sample size, examining 27 CG sites across eight candidate genes: ATP6V1C1, CES1, USP7, GABRB1, KCNQ2, LIAS, CIZ1 and GNG7. ROC curve analyses and correlation assessments with biochemical markers and drug use patterns were also performed. Significant methylation alterations were observed in GABRB1, CES1, KCNQ2 and USP7 between methamphetamine‐dependent individuals and controls. Specifically, GABRB1 and KCNQ2 showed decreased methylation, while CES1 exhibited increased methylation. USP7 displayed site‐specific changes. ROC curve analysis showed that a specific site in the GABRB1 gene demonstrated excellent diagnostic accuracy (AUC = 0.902). Methylation levels in CG sites in CES1 showed high diagnostic accuracy (AUC = 0.755) for methamphetamine dependence, while the AUC values for KCNQ2 and USP7 were 0.68 and 0.664, respectively, indicating moderate classification. Besides, the study revealed significant positive correlations between diastolic pressure and both the duration of methamphetamine use and KCNQ2 methylation levels. Additionally, USP7 methylation levels showed a positive correlation with the duration of drug use. These findings provide valuable insights for the development of diagnostic biomarkers and targeted therapeutic interventions. Future research will focus on elucidating the functional roles of these genes in the pathophysiology of methamphetamine addiction and their potential applications in treatment strategies.


  • Open Access

    Benzodiazepine Use Among Individuals with Opioid Use Disorder: A Narrative Review

    by Yue Liu, Qingxiao Hong, Xiaohu Xie, Wenwen Shen, Weisheng Chen, Huifen Liu, Wenhua Zhou

    The concomitant use of benzodiazepines (BZDs) among individuals with opioid use disorder (OUD) is highly prevalent, with a rapid annual increase in overdose-related deaths. The co-use of BZDs is a significant predictor of opioid overdose. In the absence of other drugs, BZDs are rarely the sole cause of death. Prolonged BZD use frequently results in the rapid development of tolerance and dependence. A strong association has also been established between BZD misuse and depression. Moreover, chronic BZD exposure is linked to cognitive impairments, psychomotor disturbance, delirium, and an increased risk of falls, fractures, injuries, and traffic accidents. Outpatient clinicians should routinely screen for concurrent BZD use and exercise caution in prescribing. Timely interventions—including patient education, gradual discontinuation, psychological therapies, and skills-based training—are critical to mitigating harm and improving prognosis. In addition, Traditional Chinese Medicine(TCM), including herbal prescriptions and acupuncture, may serve as promising non-addictive alternatives for the management of anxiety, insomnia, and withdrawal-related symptoms. Strengthening multifaceted efforts will be crucial for reducing the burden of BZD use and improving treatment outcomes in OUD.


  • Open Access

    Association Between the (GT)26 Allele in the GRIN2A Promoter and Opioid Use Disorder

    by Xiaohu Xie, Dingding Zhuang, Longhui Li, Tingting Wu, Wenwen Shen, Yue Liu, Wenjin Xu, Qingxiao Hong, Zemin Xu, Weisheng Chen, et al.

    Objective N-methyl-D-aspartate (NMDA) receptors are involved in the development of opioid use disorder. The (GT)n polymorphism (rs3219790) in the NMDA receptor 2A subunit gene (GRIN2A) has been proposed as a potential biomarker for risk of opioid use disorder. In this case-control study, we investigated the association between rs3219790 and opioid use disorder in a Chinese Han population.Methods A total of 538 heroin dependent patients and 400 healthy controls were recruited. The genotypes of (GT)n repeats were determined using a polymerase chain reaction-amplifying fragment length polymorphism assay. The association of the (GT)n polymorphism with opioid use disorder and cravings was assessed.Results The frequency of the (GT)26 allele in patients with opioid use disorder was significantly greater than that in the controls (p=0.029, odds ratio=1.264, 95% confidence interval=1.025–1.560), consistent with previous findings. Compared with homozygous carriers of short alleles, carriers of long alleles demonstrated significantly stronger drug cravings (p<0.05).Conclusion The results confirm that the (GT)26 allele of rs3219790 in the GRIN2A promoter is associated with opioid use disorder. Additionally, a longer rs3219790 allele is correlated with stronger drug cravings.


  • Association of GABA receptor delta subunit gene variations with increased risk of methamphetamine dependence

    by Xiaohu Xie, Dingding Zhuang, Jun Gu, Tingting Wu, Wenwen Shen, Longhui Li, Yue Liu, Wenjin Xu, Qingxiao Hong, Zemin Xu, et al.


  • Open Access

    Association between rs1799971 in the mu opioid receptor gene and methadone maintenance treatment response

    by Xiaohu Xie, Jun Gu, Dingding Zhuang, Yun Zhou, Xiaoyu Chen, Wenwen Shen, Longhui Li, Yue Liu, Wenjin Xu, Qingxiao Hong, et al.

    Objective: Genetic variations can affect individual response to methadone maintenance treatment (MMT) for heroin addiction. The A118G variant (rs1799971) in the mu opioid receptor gene (OPRM1) is a potential candidate single nucleotide polymorphism (SNP) for personalized MMT. This study determined whether rs1799971 is related to MMT response or dose.Methods: We recruited 286 MMT patients from a Han Chinese population. The rs1799971 genotype was determined via TaqMan genotyping assay. The genetic effect of this SNP on MMT response or dose was evaluated using logistic regression. A meta‐analysis was performed to merge all available data to evaluate the role of rs1799971 in MMT using RevMan 5.3 software.Results: No statistical significance was observed in the association between the OPRM1 rs1799971 and MMT response or dose in our Chinese cohort. Meta‐analysis indicated that the OPRM1 A118G variation was not significantly associated with MMT response or dose requirement.Conclusion: The results suggest that rs1799971 in OPRM1 might not play a critical role alone in influencing MMT response or dose.


  • Association Study of Genetic Polymorphisms in GABRD with Treatment Response and Dose in Methadone Maintenance Treatment

    by Xiaohu Xie, Jun Gu, Dingding Zhuang, Xiaoyu Chen, Yun Zhou, Wenwen Shen, Longhui Li, Yue Liu, Wenjin Xu, Qingxiao Hong, et al.

    Aim: This study determined if gene variants in the GABA receptor delta subunit (GABRD) are associated with treatment response and dose in methadone maintenance treatment (MMT) for heroin addiction.... Lay abstract This study determined if gene variants in the GABA receptor delta subunit (GABRD) are associated with treatment response and dose in methadone maintenance treatment (MMT) for heroin ad...


  • Association between GABA receptor delta subunit gene polymorphisms and heroin addiction

    by Xiaohu Xie, Jun Gu, Dingding Zhuang, Wenwen Shen, Longhui Li, Yue Liu, Wenjin Xu, Qingxiao Hong, Weisheng Chen, Wenhua Zhou, et al.


  • Open Access

    Hypermethylation of the κ1 opioid receptor promoter in Chinese heroin and methamphetamine addicts

    by Huihui Ji, Guili Liu, Xuting Xu, Huifen Liu, Lei Xu, Haochang Hu, Yingmin Chen, Qinxiao Hong, Qinwen Wang, Wenwen Shen, et al.

    Heroin and methamphetamine (METH) addiction continues to be a major social, economic and therapeutic problem worldwide. The opioid pathway may mediate the effects of addictive drugs. However, the potential correlation between the κ1 opioid receptor (OPRK1) and drug addiction has not yet been characterized. The aim of the present study was to investigate the potential association between methylation of the OPRK1 promoter and substance abuse. Bisulfite pyrosequencing technology was used to determine the levels of OPRK1 promoter methylation in 60 drug abusers (30 heroin and 30 METH addicts) and 52 controls, observed to exhibit no significant differences in age or gender. The results indicated that levels of OPRK1 promoter methylation were significantly higher in drug addicts when compared with controls (P=2.43x10‑4). Significant correlations between OPRK1 promoter methylation and the length and frequency of drug use were also observed in male heroin addicts (length: r=0.661, P=0.007; frequency: r=‑0.684, P=0.005). In addition, a luciferase reporter gene assay indicated that the OPRK1 promoter fragment was able to regulate gene expression (fold change between two groups >32.12, P≤0.0001). In conclusion, results of the present study indicate that methylation of the OPRK1 promoter contributes to the pathophysiology of drug addiction.